Integra LifeSciences Holdings
$ 10.39
-1.61%
04 Mar - close price
- Market Cap 809,768,000 USD
- Current Price $ 10.39
- High / Low $ 10.80 / 10.31
- Stock P/E N/A
- Book Value 13.40
- EPS -6.74
- Next Earning Report 2026-04-29
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE -0.40 %
- 52 Week High 24.36
- 52 Week Low 9.96
About
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, limb reconstruction, orthopedics, and general surgery. The company is headquartered in Princeton, New Jersey.
Analyst Target Price
$15.12
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-26 | 2025-10-30 | 2025-07-31 | 2025-05-05 | 2025-02-26 | 2024-11-04 | 2024-07-29 | 2024-05-06 | 2024-02-28 | 2023-10-25 | 2023-07-26 | 2023-04-26 |
| Reported EPS | 0.83 | 0.54 | 0.45 | -0.3308 | 0.97 | 0.41 | 0.63 | 0.55 | 0.89 | 0.76 | 0.71 | 0.74 |
| Estimated EPS | 0.8002 | 0.43 | 0.44 | 0.4311 | 0.8554 | 0.39 | 0.62 | 0.55 | 0.9 | 0.78 | 0.57 | 0.74 |
| Surprise | 0.0298 | 0.11 | 0.01 | -0.7619 | 0.1146 | 0.02 | 0.01 | 0 | -0.01 | -0.02 | 0.14 | 0 |
| Surprise Percentage | 3.7241% | 25.5814% | 2.2727% | -176.7339% | 13.3972% | 5.1282% | 1.6129% | 0% | -1.1111% | -2.5641% | 24.5614% | 0% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-29 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.484 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | |
|---|---|
| Payment Date | None |
| Amount | $6.37 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IART
2026-03-02 22:51:37
Integra LifeSciences Holdings Corp. experienced a significant 8.37% gap down at market open, contributing to a 2.24% daily decline and a 1.82% monthly downturn, contrasting with the S&P 500's performance. The company, a small-cap player in the Pharmaceuticals & Biotechnology sector, has a market capitalization of USD 1,011 million, a P/E ratio of 9.00, and a debt-to-equity ratio of 1.52, with no dividend yield. Technical indicators, including moving averages, MACD, KST, and Bollinger Bands, reflect a bearish sentiment for the stock.
2026-03-02 15:12:00
Integra LifeSciences Holdings Corp. has experienced significant stock performance declines over the past year and three years, despite a modest monthly gain. The company's year-to-date results are unfavorable compared to the S&P 500, and technical indicators suggest a bearish sentiment. Investors will closely monitor its performance amidst these market challenges.
2026-03-02 14:52:50
Integra LifeSciences Holdings Corporation (NASDAQ:IART) has received a consensus "Reduce" recommendation from seven research firms, with an average 12-month price target of $14.80. This comes despite the company slightly beating Q4 earnings and revenue estimates, as it still maintains a negative net margin and its FY2026 guidance is below analyst expectations. Institutional investors have actively traded the stock, with several hedge funds increasing their holdings.
2026-02-27 13:52:03
Integra LifeSciences reported Q4 2025 earnings, exceeding EPS expectations at $0.83 against a $0.79 forecast. The company outlined its strategic imperatives for 2026, focusing on strengthening quality, supply chain reliability, accelerating growth, and igniting innovation, while navigating tariff uncertainties and continuing remediation efforts for certain products like MediHoney. Despite some operational challenges and supply constraints impacting organic growth, the underlying demand for its products remains strong, with key products like SurgiMend expected to relaunch in Q4 2026.
2026-02-26 22:52:33
Integra LifeSciences reported a significant Q4 and full-year 2025 financial performance, including a GAAP net loss of $(6.74) per share for the full year, primarily due to a $511 million goodwill impairment charge. The company attributed this impairment to a decline in share price reflecting external and operational factors like tariff changes, quality, operational, and supply-related challenges. Despite these setbacks and an organic revenue decline, Integra provided 2026 guidance expecting revenues between $1,662 million and $1,702 million and adjusted EPS of $2.30 to $2.40.
2026-02-26 22:51:37
Integra LifeSciences (NASDAQ:IART) reported better-than-expected revenue and adjusted EPS for Q4 CY2025, with sales of $434.9 million and adjusted EPS of $0.83, surpassing analyst estimates. Despite the beat, revenue saw a 1.7% year-on-year decline, and Q1 CY2026 revenue guidance fell below expectations. The company's operating margin decreased significantly compared to the prior year, indicating rising expenses relative to revenue.
